Human leucocyte interferon-alpha in the treatment of chronic hepatitis C

Digestive and Liver Disease

Volumn 33, Issue 4, 2001, Pages 347-352

  Mazzoran, L ^a   Zorat, F ^a   Chemello, L ^a,b   Croce L S ^a   Rigato, I ^a   Cavalleto, L ^a,b   Bernardinello, E ^a,b   Tiribelli, C ^a   Alberti, A ^a,b   Pozzato, G ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiviral therapy; Chronic hepatitis C; Human leucocyte interferon alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; RECOMBINANT ALPHA INTERFERON; VIRUS RNA;

ADULT; AGE; ANOREXIA; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RNA, VIRAL; TIME FACTORS;

EID: 0034975537     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80090-6     Document Type: Article

References (36)

1. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
2. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
3. Recombinant alfa-interferon treatment of non-A non-B (type C) hepatitis: Review of studies and recommendations for treatment
4. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon alfa-2
5. Breakthrough during interferon therapy for chronic hepatitis C. Overview on the diagnosis, possible etiology and recommendations for management
6. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C
7. Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C
8. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A non-B hepatitis
9. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection
10. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN
11. Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis
12. Interferon alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha
13. Leucocyte interferon-α retreatment for chronic hepatitis C patients previously intolerant to other interferons
14. Retreatment with human leucocyte interferon alpha of chronic hepatitis C, recurring after a first cycle with recombinant interferon
15. Leucocyte and platelet lowering by some interferon types during viral hepatitis treatment
16. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
17. Effects of the interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease
18. Production and partial purification of human immune interferon
19. Effective natural interferon-α therapy in recombinant interferon-α resistant patients with hairy cell leukemia
20. Long-term results of therapy with interferon α for type II essential mixed cryoglobulinemia
21. Treatment of anti-recombinant interferon alpha2 antibody positive CML patients with natural interferon alfa
22. Human leucocyte interferon α therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon α2a
23. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients
24. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells
25. A prospective randomized trial comparing lymphoblastoid to recombinant interferon alfa2a as therapy for chronic hepatitis C
26. A randomized, double-blind, controlled, multicentre trial of human lymphoblastoid interferon alpha in the treatment of adult with chronic hepatitis non-A non-B (C)
27. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection
28. Predictive factors in the response to interferon therapy in chronic hepatitis C
29. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C
30. Interferon alfa for chronic hepatitis C: An analysis of pretreatment clinical predictor of response
31. Viral and host factor that contribute to efficacy of interferon alfa-2a therapy in patients with chronic hepatitis C
32. Comparative efficacy of interferon alfa in cirrhotic and non cirrhotic patients with non-A non-B hepatitis
33. Interferon therapy in chronic hepatitis C: Evidence of different outcome with respect to different viral strain
34. Randomized trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
35. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C